CN Patent

CN112390793B — Cdk6/dyrk2双靶点抑制剂及其制备方法和应用

Assigned to Jiangsu Tasly Diyi Pharmaceutical Co Ltd · Expires 2021-04-27 · 5y expired

What this patent protects

本发明公开了一种由下述通式（I）所示的化合物或其药学上可接受的盐。本发明还公开了上述化合物的制备方法及其在预防和/或治疗癌症或肿瘤相关疾病中应用，特别是乳腺癌、前列腺癌、肺癌、多发性骨髓瘤、白血病、胃癌、卵巢癌、结肠癌、肝癌、胰腺癌以及人神经胶质瘤等疾病。本发明的化合物有望开发成新一代的抗癌药物。

USPTO Abstract

本发明公开了一种由下述通式（I）所示的化合物或其药学上可接受的盐。本发明还公开了上述化合物的制备方法及其在预防和/或治疗癌症或肿瘤相关疾病中应用，特别是乳腺癌、前列腺癌、肺癌、多发性骨髓瘤、白血病、胃癌、卵巢癌、结肠癌、肝癌、胰腺癌以及人神经胶质瘤等疾病。本发明的化合物有望开发成新一代的抗癌药物。

Drugs covered by this patent

Patent Metadata

Patent number
CN112390793B
Jurisdiction
CN
Classification
—
Expires
2021-04-27
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Tasly Diyi Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.